Premium
Transthyretin amyloidosis with cardiomyopathy after domino liver transplantation: Results of a cross‐sectional study
Author(s) -
GrandeTrillo Antonio,
Baliellas Carmen,
Lladó Laura,
Casasnovas Carlos,
FrancoBaux Joaquín V.,
GraciaSánchez Laura,
GómezBravo Miguel Á.,
GonzálezVilatarsana Emma,
CaballeroGullón Luis,
Echeverri Eduardo,
GonzálezCostello José
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16216
Subject(s) - medicine , cardiac amyloidosis , transthyretin , amyloidosis , cardiomyopathy , bone scintigraphy , scintigraphy , transplantation , restrictive cardiomyopathy , liver transplantation , context (archaeology) , diabetes mellitus , cardiology , heart failure , radiology , endocrinology , paleontology , biology
Domino liver transplantation (DLT) has been used widely in patients with hereditary amyloid transthyretin (ATTR) amyloidosis. New‐onset polyneuropathy in recipients of DLT has been reported, but there are few cases of cardiac involvement reported. We aimed to perform a cross‐sectional study for ATTR amyloidosis with cardiomyopathy (ATTR‐CM) in DLT recipients. We evaluated 23 living DLT recipients a median of 9 years since DLT at 2 referral centers with a systematic cardiac evaluation, including bone scintigraphy. Median age was 72 years, 91% had hypertension, 35% had diabetes mellitus, 67% had chronic renal failure, and 8 patients (35%) developed new‐onset polyneuropathy. Only 13% had a normal electrocardiogram and a normal echocardiography, and most of them showed some conduction disturbance or increase in left ventricular wall thickness, but only 1 patient with a Glu89Lys mutation developed ATTR‐CM diagnosed by bone scintigraphy and endomyocardial biopsy. None of the recipients of a DLT with Val30Met mutation showed cardiac involvement by bone scintigraphy. In conclusion, DLT from Val30Met donors seems to be safe regarding the development of ATTR‐CM. Evaluation of cardiomyopathy in DLT recipients is challenging due to concomitant comorbidities and in this context, bone scintigraphy can be helpful to evaluate ATTR‐CM.